ENTRADA THERAPEUTICS, INC.

$10.76 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About ENTRADA THERAPEUTICS, INC.

Entrada Therapeutics, Inc. (Entrada) is a biopharmaceutical company aiming to transform the lives of patients by establishing a set of medicines, Endosomal Escape Vehicles (EEV) therapeutics, to engage intracellular targets that are considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.

Stock Analysis

last close $10.85
1-mo return -8.1%
3-mo return 75.3%
avg daily vol. 71.06T
52-week high 36.85
52-week low 5.12
market cap. $340M
forward pe -
annual div. -
roe -39.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 82.6%
baraka

Subscribe now for daily local and international financial news

Subscribe